Perspectives on HCV Cure

  • Michael J. SofiaEmail author
Part of the Topics in Medicinal Chemistry book series (TMC, volume 32)


The development of interferon-free cures for hepatitis C has revolutionized the treatment of patients chronically infected with the hepatitis C virus. Since 2010, ten new curative regimens have been introduced into clinical practice. These new regimens have delivered cure rates in excess of 95% in as little as 8–10 weeks on therapy. Never before has there been an absolute cure for a chronic viral disease. This medical breakthrough has been made possible by the commitment of scientists and clinicians from both academia and industry working toward a common goal. Because of the availability of these curative regimens, it is now possible to contemplate eliminating HCV as a global public health problem as outlined by the World Health Organization. This perspective will give a brief commentary of the achievements and future possibilities provided by direct-acting antiviral interferon-free HCV cure therapies.


HCV cure therapies HCV elimination Hepatitis C Hepatitis C virus Interferon-free HCV therapy WHO HCV elimination program 


Compliance with Ethical Standards

Conflict of Interest: Author is co-founder, Chief Scientific Officer and shareholder of Arbutus Biopharma, Inc. Author is a consultant for Gilead Sciences, Inc. Author was an employee of Pharmasset Inc. and Gilead Sciences Inc.

Ethical Approval: This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Lledo GM, Carrasco I, Benitez-Gutierrez LM, Arias A, Royuela A, Requena S, Cuervas-Mons V, de Mendoza C (2018) Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection. AIDS 32(16):2347–2352PubMedGoogle Scholar
  2. 2.
    El-Raziky M, Khairy M, Fouad A, Salama A, Elsharkawy A, Tantawy O (2018) Effect of direct-acting agents on fibrosis regression in chronic hepatitis C virus patients’ treatment compared with interferon-containing regimens. J Interferon Cytokine Res 38(3):129–136CrossRefGoogle Scholar
  3. 3.
    Foster GR, Irving WL, Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WT, MacDonald DC, Agarwal K, HCV Research UK (2016) Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64(6):1224–1231CrossRefGoogle Scholar
  4. 4.
    Pradat P, Virlogeux V, Trepo E (2018) Epidemiology and elimination of HCV-related liver disease. Viruses 10(10):E545CrossRefGoogle Scholar
  5. 5.
    Salmon D, Mondelli MU, Maticic M, Arends JE, ESCMID Study Group for Viral Hepatitis (2018) The benefits of hepatitis C virus cure: every rose has thorns. J Viral Hepat 25(4):320–328CrossRefGoogle Scholar
  6. 6.
    Younossi ZM, Stepanova M, Henry L, Han KH, Ahn SH, Lim YS, Chuang WL, Kao JH, Kinh N, Lai CL, Yuen MF, Chan HL, Lai W (2018) The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. Liver Int 38(7):1179–1187CrossRefGoogle Scholar
  7. 7.
    Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG (2018) Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol 11(5):519–524CrossRefGoogle Scholar
  8. 8.
    Juanbeltz R, Martinez-Baz I, San Miguel R, Goni-Esarte S, Cabases JM, Castilla J (2018) Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS One 13(10):e0205277CrossRefGoogle Scholar
  9. 9.
    van Tilborg M, Maan R, van der Meer AJ, de Knegt RJ (2017) Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. Best Pract Res Clin Gastroenterol 31(2):219–225CrossRefGoogle Scholar
  10. 10.
    Sonali P, Cotter T, Sandikci B, Couri T, Little EC, Sundaram V, Bodzin A, Charlton M (2018) Increasing utilization and excellent early outcomes following liver transplant of HCV viremic donors into HCV positive and negative recipients. The liver meeting 2018, San Francisco, CA, November 9–13Google Scholar
  11. 11.
    Sulkowski M, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, Ni L, Svarovskaia E, Brainard D, Symonds W, Subramanian GM, McHutchinson JG, Rodriguez-Torres M, Deiterich D (2014) Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312(4):353–361CrossRefGoogle Scholar
  12. 12.
    Keating GM (2015) Ledipasvir/sofosbuvir: a review of its use in chronic hepatitis C. Drugs 75:675–685CrossRefGoogle Scholar
  13. 13.
    Geneva: World Health Organization (2017) Global health report, 2017Google Scholar
  14. 14.
    Grebely J, Dore GJ, Morin S, Rockstroh JK, Klein MB (2017) Elimination of HCV as a public health concern among people who inject drugs by 2030 – what will it take to get there? J Int AIDS Soc 20(1):22146CrossRefGoogle Scholar
  15. 15.
    Henry B (2018) Drug pricing & challenges to hepatitis C treatment access. J Health Biomed Law 14:265–283PubMedPubMedCentralGoogle Scholar
  16. 16.
    Rodriguez C, Reynolds A (2016) Accessing the cure: helping patients with hepatitis C overcome barriers to care. Am J Manag Care 22(4 Suppl):s108–s112PubMedGoogle Scholar
  17. 17.
    Online HC (2018) Cost and access to direct-acting antiviral agents. Accessed 29 Nov 2018
  18. 18.
    DiMasi JA, Feldman L, Seckler A, Wilson A (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87(3):272–277CrossRefGoogle Scholar
  19. 19.
    Bailey JR, Barnes E, Cox AL (2019) Approaches, progress, and challenges to hepatitis C vaccine development. Gastroenterology 156(2):418–430CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Arbutus Biopharma, Inc.WarminsterUSA

Personalised recommendations